This comprehensive reference work edited by one of the leading authorities on obesity presents an up-to-date survey of the current scientific understanding of the metabolic syndrome, as well as an overview of the most significant changes to the field over the past 30 years. This volume is a thorough reference for obesity and the metabolic syndrome and will prove an indispensable resource for clinicians and researchers at levels worldwide. The obesity epidemic has generated immense interest in recent years due to the wide-ranging and significant adverse health and economic consequences that surround the problem. Much attention has been focused on behaviors that lead to obesity, in particular to over consumption of energy-dense food and to sedentary lifestyle. However, obesity is an extremely complex condition with poorly defined pathogenesis. In addition, when combined with other comorbidities such as hypertension and dyslipidemia, obesity often leads to a patient diagnosis of metabolic syndrome, a very troubling condition that has grown, and is continuing to grow, rapidly each year in prevalence worldwide. Metabolic syndrome is a cluster of conditions — increased blood pressure, a high blood sugar level, excess body fat around the waist and abnormal cholesterol levels — that occur together, increasing one’s risk of heart disease, stroke and diabetes. This resource covers the full range of scientific and clinical aspects: epidemiology, genetics, environmental factors, pathophysiology, diseases associated with obesity, and clinical management.
Provides a comprehensive overview to the basic science and clinical aspects of the topic
Offers thorough, up-to-date epidemiology data in all key regions worldwide
Discusses the standard of care for both pharmacologic and nonpharmacologic treatment of metabolic syndrome
Foreword Preface Part 1: Epidemiology (i) Overview: Definition, prevalence in adults and children, morbidity, mortality (ii) Obesity and metabolic syndrome in North America (iii) Obesity and metabolic syndrome in Europe (iv) Obesity and metabolic syndrome in Latin America (v) Obesity and metabolic syndrome in Sub-Saharan Africa (v) Obesity and metabolic syndrome in the Middle East (vi) Obesity and metabolic syndrome in Asia (vii) Obesity and metabolic syndrome in Australia, New Zealand and Polynesia Part 2: Genetics (i) Genetics of obesity (ii) Genetics of type 2 diabetes (iii) Genetics of lipid disorders (iv) Genetics of atherosclerosis Part 3: Environmental factors (i) Gestational factors, obesity and metabolic syndrome (ii) Influence of early postnatal environment on obesity and metabolic syndrome (breast feeding, weaning, family environment) (iii) Diet, obesity and metabolic syndrome (calories, macronutrients, high fructose corn syrup, micronutrients) (iv) Exercise and non-exercise physical activity, obesity and metabolic syndrome (v) Influence of housing, transportation, TV and electronic media on obesity and metabolic syndrome (vi) Social and community networks, obesity and metabolic syndrome Part 4: Pathophysiology (i) Energy homeostasis (ii) Metabolism of carbohydrate, proteins and lipids (iii) CNS regulation of feeding and energy homeostasis (iv) Adipose tissue (structure, WAT and BAT, adipokines, fuel metabolism) (v) Gut pathophysiology (motor, exocrine, endocrine) (vi) Endocrine pancreas (alpha, beta , other cells, insulin defects in obesity) (vii) Insulin resistance and metabolic syndrome (viii) Gut microbiome, obesity and metabolism (ix) Atherogenic dyslipidemia (x) Inflammation, endothelial dysfunction, and atherogenesis (xi) Skeletal muscle, myokines and metabolism (xii) Sleep, circadian rhythms and metabolism Part 5: Diseases associated with obesity (i) Type 2 diabetes (natural history, pathogenesis, assessment of insulin resistance and beta cell dysfunction, treatment) (ii) Cardiovascular morbidity (CAD; stroke) (iii) Non-alcoholic fatty liver disease (iv) Obstructive sleep apnea, obesity and metabolic syndrome (v) Obesity, GERD, Barrett’s esophagus (vii) Connecting metabolic syndrome and cancer (viii) Sarcopenic obesity (ix) Obesity, PCOS and infertility (x) Endocrinopathies associated with obesity (insulin, thyroid, glucocorticoids, growth hormone) (xi) Obesity, metabolic syndrome and dementia Part 6: Management (i) Assessment of obesity and cardiometabolic risk (body composition, laboratory investigation, imaging, novel biomarkers) (ii) Diet, exercise, behavior therapy (iii) Pharmacotherapy (iv) Bariatric surgery (v) Childhood interventions (school –based and other programs) (vi) Community, national and global interventions